Scratching beneath the surface: IL4Ra blockade and the progression from myocardial ischemic injury to heart failure.

This article explores the role of IL4Ra signaling in the development of heart failure following myocardial ischemic injury. The authors conducted studies on mice and found that administering IL4 and IL13 after a heart attack improved cardiac function. They also created a mouse model with a knockout of the IL4Ra receptor and observed that these mice experienced greater deterioration of cardiac function compared to control mice. Additionally, the authors conducted retrospective studies on patients using a drug called dupilumab, which targets the IL4Ra receptor, and found that these patients had a lower risk of developing heart disease, heart failure, or cerebrovascular events. The authors conclude that IL4Ra signaling plays a protective role in preventing the progression to heart failure after an ischemic event. They also discuss the potential cardiac side effects of dupilumab and suggest the need for further research to develop targeted therapies that can mitigate these effects while effectively treating atopic dermatitis. [Extracted from the article]

Copyright of American Journal of Physiology: Heart & Circulatory Physiology is the property of American Physiological Society and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)